ClinicalTrials.gg
Status unknownNCT04488848ERGEUpdated Jan 27, 2021

Cardiometabolic Effects of Rapid Glucose Excursion

An interventional study of bolus glucose and continuous clucose in Diabetes Mellitus, Experimental, sponsored by Barmherzige Brüder Linz. Status unknown at 1 site in Austria. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-27.

Sponsored by Barmherzige Brüder Linz · Not applicable, Interventional, and Basic science

How we know

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Apr 2019, registered Aug 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

The effects of rapid glucose excursions, induced by intravenous bolus application of glucose in healthy probands, on cardiometabolic and inflammatory parameters will be investigated

Read the detailed description

BACKGROUND: It is well known that people with diabetes have a five times higher risk of dying of cardiovascular death than non-diabetics. However not only hyperglycaemia per se but also glycaemic variability is currently particularly regarded as a risk factor for cardiovascular and microvascular complications. Intermittent blood sugar excursions with pronounced fluctuations between high and low values instead of constant, even increased blood sugar exposure, have been shown to be more harmful in several studies.

AIM: The aim of this study is to determine the effect of rapid glucose excursion versus continuous glucose infusion on cardiovascular and metabolic parameters in healthy volunteers.

METHODS/DESIGN: In this study, ten healthy male subjects will be studied on two occasions. In a random order the subjects will receive 3 times 20 grams of glucose intravenously as a bolus or, on the other occasion, 60 grams of glucose continuously over 3 hours. Cardiometabolic biomarkers will be analysed serially to analyse the effects of glucose excursions.

PROSPECT: Glycaemic variability may be a crucial factor in the development of diabetic complications, but there is currently a lack of conclusive evidence. The causes and mechanisms of these negative influences on the cardiovascular system due to high glucose variability have not been sufficiently investigated and are therefore not fully understood so far. To date, however, there have been no studies with acutely altered glucose concentrations in healthy volunteers that have investigated the effects on traditional as well as recently identified cardiovascular and metabolic biomarkers. Knowledge of such effects may improve the therapeutic strategy in diabetic patients.

02

Conditions studied

  • Diabetes Mellitus, Experimental
03

In context

Lead sponsor

Barmherzige Brüder Linz is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged 18 years or older with no disease history
  • written

Exclusion criteria

Exclusion Criteria:

  • receiving any medication
  • probands who suffer from infectious disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Placebo comparator
    continous glucose

    continous glucose infusion (60 grams over 3 hours)

    Other: continuous clucose

  • Experimental
    bolus (excursion)

    3 x 20 grams of glucose as a bolus over 6 minutes at t0, 60 minutes and 120 minutes

    Other: bolus glucose

Interventions

  • Otherbolus glucose

    bolus Glucose

  • Othercontinuous clucose

    continuous clucose

06

What researchers measure

Primary outcomes

  1. Interleukin-6

    measurement of the concentration of IL-6 (parameter of inflammation) in the serum over time following infusion

    Time frame: 48 hours

07

Study locations

1 of 1 sites recruiting
  • Barmherzige Brüder Linz - Innere Medizin
    Linz, 4021, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Dec 2020, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2019
First posted
Jul 28, 2020
StartActual
Apr 11, 2019
Primary completionActual
Dec 31, 2020
CompletionEst.
Jul 2021
Last update
Jan 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04488848
Lead sponsor
Barmherzige Brüder Linz
Responsible party
Sponsor
First posted
Jul 28, 2020
Start date
Apr 11, 2019
Primary completion
Dec 31, 2020
Completion
Jul 2021 (estimated)
Last update
Jan 27, 2021

Study contacts

Matthias Heinzl, MD
Contact
matthias.heinzl@gmx.at
+43732789721236
Martin Clodi, MD, Prof.
Contact
martin.clodi@clodi.at
+43732789724305

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion